-

Nomic Bio Appoints Byron Hewett to its Board of Directors

MONTREAL--(BUSINESS WIRE)--Nomic Bio, a pioneering protein profiling company, today announced the appointment of Byron Hewett to its board of directors. Hewett brings invaluable operational and strategic expertise to guide Nomic Bio through its crucial years of growth.

“We are thrilled to welcome Byron to Nomic’s board of directors as we commercialize and continue to scale our nELISA platform,” said Milad Dagher, CEO and co-founder of Nomic Bio. “Byron is a veteran in the tools space and his decades of experience and strategic insights will be instrumental during this next pivotal phase of growth.”

Mr. Hewett has more than 30 years of experience leading the development and commercialization of research and diagnostic tools. Most recently, he was CEO and Co-founder at Brava Diagnostics, focusing on point-of-care diagnostics. Previously, he was CEO of SomaLogic, a publicly listed proteomics company and Chairman and CEO of BioBehavioral Diagnostics, respectively. He was also CEO at Immunicon, and held senior roles at Qiagen, Bayer Diagnostics and Chiron Diagnostics.

“I have been following the progress of Nomic Bio for several years now and I’ve been quite impressed,” said Hewett. “Nomic's nELISA platform addresses several of the industry’s bottlenecks in a scalable and versatile manner, and I look forward to collaborating with the team as we drive the company's growth and expand its impact in the industry.”

The addition of Byron Hewett to Nomic Bio's board of directors further solidifies the company's position as a leader in the protein discovery space. Hewett will play a pivotal role in shaping the company's strategic direction and accelerating its mission to revolutionize drug development and diagnostics.

About Nomic Bio
Nomic Bio is dedicated to making proteomics as accessible as genomics. Leveraging its nELISA platform, the company aims to dramatically accelerate the discovery and development of new drugs and diagnostics. Currently, Nomic Bio offers the most comprehensive inflammatory secretome panel on the market to over 30 pharmas and biotechs, and it is continuously expanding its protein content to cover more of the proteome. Nomic Bio is headquartered in Montreal, with additional labs and offices in Boston, and it is backed by top-tier venture capital firms, including Lux Capital, SR One, and Casdin Capital.

Contacts

press@nomic.bio

Industry:

Nomic Bio

Release Summary
Nomic Bio, a company democratizing proteomics for drug discovery, announces seasoned vet Byron Hewett as a new member of its Board of Directors.
Release Versions
English
Hashtags
#proteinprofiling
#proteomics

Contacts

press@nomic.bio

Social Media Profiles
Nomic on LinkedIn
@nomicbio
More News From Nomic Bio

Nomic joins the HESI Global OASIS Consortium to Advance Human-Relevant Safety Assessment Through Proteomics

MONTREAL--(BUSINESS WIRE)--Nomic Bio Inc., today announced they will partner with the Health and Environmental Sciences Institute’s (HESI Global) Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium to identify biomarker signatures for liver toxicity using large-scale protein profiling of human liver-derived cell models. The OASIS Consortium is designed to support more predictive, efficient, and human-relevant approaches to compound safety assessment, consistent with the grow...

Nomic and Wellcome Sanger Institute Collaborate to Bring Protein-Level Resolution to the Genetics of Immune Diversity

MONTREAL--(BUSINESS WIRE)--Nomic Bio Inc. announced a research collaboration with the Wellcome Sanger Institute to perform large-scale proteomic profiling of human-derived peripheral blood mononuclear cell (PBMC) supernatant samples generated through Project JAGUAR. By integrating proteomic data with genetic and transcriptomic information from these experiments, the collaboration aims to build one of the most comprehensive functional atlases of human immune variation to date. Project JAGUAR is...

Nomic and Broad Clinical Labs Partner to Integrate Omni 1000 into Discovery and Translational Workflows

MONTREAL--(BUSINESS WIRE)--Nomic Bio today announced a partnership with Broad Clinical Labs (BCL) to integrate the Nomic platform into its multi-omic workflows, reshaping how scalable, high-throughput proteomics is delivered. Having profiled close to 1 million samples for biopharma and academic customers through its core profiling service, this partnership builds on that foundation by bringing the platform into select organizations to support the development of new applications and workflows. T...
Back to Newsroom